

Ezza Fatima Tariq MD¹, Sarmad Zain MBBS², Ahmad Ali Khan MBBS², Ahmad Kabi Hughal MBBS³, Choudhury Shadmani MD⁴, Jonathan Arnold MD^{1,5} Affiliations:UPMC McKeesport¹, Nishtar Medical University², CPE Institute of Cardiology³, Indiana Regional Medical Centre⁴, University of Pittsburgh⁵


INTRODUCTION

Myelin oligodendrocyte glycoprotein Antibody disease (MOGAD) is a CNS demyelination disorder that has a presentation very similar to Multiple sclerosis (MS) and can easily be mistaken for MS, causing a diagnostic dilemma.

CASE PRESENTATION


PATIENT	 30 year old woman Multiple comorbidities (Migrai anxiety disorder)
<section-header><section-header></section-header></section-header>	 Abdominal pain (sharp, radiatin back) Pain shoots down back on neck Lower extremity numbness – progressed from right leg to left Bowel and urine incontinence
IMAGING	 Thoracic MRI without contrast (increased T2 signal at T5, T9 lev and C5 levels, demyelinating longitudinal plaque Brain MRI unremarkable.
DIAGNOSTIC TEST	 LP demonstrating oligoclonal k Positive antibodies against MC serum.
DIAGNOSIS	 Initially suspected Multiple Scle Later confirmed as MOG Antibe Disease (MOGAD).
TREATMENT	 Initially treated with steroids for (no improvement) Subsequently treated with plasmapheresis.
CLINICAL OUTCOME:	 Patient showed improvement af plasmapheresis.

Title: "The Masquerading Myelin: Unveiling MOGAD Masking as Multiple Sclerosis - A Case Report"




Cervical spine T2 sagittal image without contrast with a T2 hyperintense lesion spanning from C4 to C5 in the left hemicord (annotated by bracket). Early multilevel cervical spine degenerative disc disease. A T2 vertebral body hemangioma is incidentally noted.


POST-TREATMENT T2 SEGMENT OF THORACIC SPINE ON MRI



Cervical spine T2 sagittal image without contrast and post-treatment now lacking the T2-hyperintensity in the left hemicord.



ter





- MOGAD mimics MS, causing optic neuritis, transverse myelitis, or encephalitis.
- tends to be monophasic, while MS

Our case underscores the critical need for prompt differentiation between MS and MOGAD due to distinct clinical features, emphasizing the importance of modified treatment strategies for each condition. Relapses are more common in MS and respond to DMARD unlike MOGAD which is less likely to respond to DMARD.

REFERENCES

1. de Mol, C L et al. "The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults." Multiple sclerosis (Houndmills, Basingstoke, England) vol. 26,7 (2020): 806-814. doi:10.1177/1352458519845112

2. Jurynczyk, Maciej et al. "Clinical presentation and prognosis in MOG-antibody disease: a UK study." Brain : a journal of neurology vol. 140,12 (2017): 3128-3138. doi:10.1093/brain/awx276

DISCUSSION

University of Pittsburgh

Medical Center

MOGAD presents with bilateral spinal lesions and positive MOG antibodies, contrasting with MS brain lesions. Initial treatment is similar, but MOGAD relapses and requires ongoing therapy.

CONCLUSION